Russia: Cancer vaccine that reduces tumors by 80% awaits clinical approval.

Veronika Skvortsova, Director of the Federal Biomedical Agency of Russia (FMBA) and former Russian Minister of Health, has just announced that a new Russian cancer vaccine is awaiting clinical approval from the country's Ministry of Health.

Following successful preclinical trials of this new cancer vaccine, demonstrating both high safety and efficacy.

This vaccine has undergone preclinical studies according to international standards, lasting continuously for 3 years. The results showed that it is absolutely safe, even with repeated injections, and is highly effective in inhibiting tumor growth.

The results were astonishing; the size and growth rate of tumors could be reduced by 60-80%. Notably, the vaccine also had the potential to significantly improve patient survival rates.

The key feature of this vaccine is its ability to directly impact the immune system, helping the body recognize and fight cancer cells.

Illustration: AI

Awaiting clinical approval

By the end of summer 2025, FMBA had submitted all the necessary documents to the Russian Ministry of Health to apply for approval to use the vaccine on patients. This means that, if approved, the vaccine could begin testing in hospitals and cancer centers in a very short time, according to TASS news agency.

The first target is colorectal cancer.

Initially, the vaccine is targeted for colorectal cancer – one of the most common types of cancer worldwide. Simultaneously, scientists are also finalizing the development of a vaccine against glioblastoma – one of the most malignant tumors, and specific types of melanoma.

A cancer vaccine is ready for use.

According to Ms. Skvortsova, the highlight of this vaccine is its ability to directly affect the immune system, helping the body recognize and fight cancer cells. This is a new approach compared to traditional methods such as chemotherapy or radiation therapy.

The vaccine is ready for use; we are just waiting for the license, Skvortsova affirmed. If deployed in clinical practice, this could become one of the most important breakthroughs in Russian medicine for cancer treatment.

Source: https://thanhnien.vn/nga-vac-xin-ung-thu-giam-80-khoi-u-da-san-ready-to-use-185250907160008105.htm